Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report.

Cicek E, Cicek IE, Uguz F.

Clin Psychopharmacol Neurosci. 2017 May 31;15(2):184-186. doi: 10.9758/cpn.2017.15.2.184.

2.

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?

Ravenstijn P, Samtani M, Russu A, Hough D, Gopal S.

J Clin Psychopharmacol. 2016 Dec;36(6):744-745. No abstract available.

3.

Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.

Samtani MN, Nandy P, Ravenstijn P, Remmerie B, Vermeulen A, Russu A, D'hoore P, Baum EZ, Savitz A, Gopal S, Hough D.

Br J Clin Pharmacol. 2016 Nov;82(5):1364-1370. doi: 10.1111/bcp.13050. Epub 2016 Jul 24.

PMID:
27333588
4.
5.

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia.

Demirci K, Keleş S, Demirdaş A, Korucu CÇ.

Case Rep Psychiatry. 2015;2015:528370. doi: 10.1155/2015/528370. Epub 2015 Oct 11.

6.

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.

Kwon JS, Kim SN, Han J, Lee SI, Chang JS, Choi JS, Lee HJ, Cho SJ, Jun TY, Lee SH, Han C, Lee KU, Lee KK, Lee E.

Int Clin Psychopharmacol. 2015 Nov;30(6):320-8. doi: 10.1097/YIC.0000000000000093.

7.

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

Si T, Zhang K, Tang J, Fang M, Li K, Zhuo J, Feng Y.

Neuropsychiatr Dis Treat. 2015 Jun 22;11:1483-92. doi: 10.2147/NDT.S81760. eCollection 2015.

8.

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.

Schreiner A, Bergmans P, Cherubin P, Keim S, Llorca PM, Cosar B, Petralia A, Corrivetti G, Hargarter L.

J Psychopharmacol. 2015 Aug;29(8):910-22. doi: 10.1177/0269881115586284. Epub 2015 May 21.

9.

Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.

Gopal S, Xu H, Bossie C, Burón JA, Fu DJ, Savitz A, Nuamah I, Hough D.

Int J Clin Pract. 2014 Dec;68(12):1514-22. doi: 10.1111/ijcp.12493. Epub 2014 Oct 31.

10.

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose.

Samtani MN, Nuamah I, Gopal S, Remmerie B, Kern Sliwa J, Alphs L.

Neuropsychiatr Dis Treat. 2013;9:721-30. doi: 10.2147/NDT.S40836. Epub 2013 May 20.

11.

Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response.

Geerts H, Spiros A, Roberts P, Twyman R, Alphs L, Grace AA.

PLoS One. 2012;7(12):e49732. doi: 10.1371/journal.pone.0049732. Epub 2012 Dec 14.

12.

Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.

Samtani MN, Sheehan JJ, Fu DJ, Remmerie B, Sliwa JK, Alphs L.

Clin Pharmacol. 2012;4:25-40. doi: 10.2147/CPAA.S32735. Epub 2012 Jul 16. Erratum in: Clin Pharmacol. 2012;4:51.

13.

Summary workshop report: Facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalence.

Polli JE, Cook JA, Davit BM, Dickinson PA, Argenti D, Barbour N, García-Arieta A, Geoffroy JM, Hartauer K, Li S, Mitra A, Muller FX, Purohit V, Sanchez-Felix M, Skoug JW, Tang K.

AAPS J. 2012 Sep;14(3):627-38. doi: 10.1208/s12248-012-9376-z. Epub 2012 Jun 9.

14.

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G.

BMC Psychiatry. 2012 Mar 28;12:26. doi: 10.1186/1471-244X-12-26.

Supplemental Content

Support Center